Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety studySherko Kuemmel, Miguel Martín, Jacinta Abraham et al.|Breast Cancer Research and Treatment|2021Cited by 23